Blocking the activity of an enzyme known as MELK may help boost the production of platelets — tiny cell fragments that improve blood clotting and…
Adding Cablivi (caplacizumab-yhdp) to standard treatment for immune-mediated thrombotic thrombocytopenic purpura (iTTP) may help protect the brain by repairing damage to the blood-brain barrier, potentially reducing long-term cognitive problems, a study suggests. The study, “Neurological Impact of Caplacizumab in Refractory iTTP Survivors: A Comparative Study of Blood-Brain-Barrier Integrity…
Latest news & perspectives
Women with von Willebrand disease (VWD) still experienced a high burden of heavy menstrual bleeding despite commonly using first-line therapies such as tranexamic acid…
